Inflammasome and IL-1β-Mediated Disorders
The NLRP3 inflammasome is an intracellular complex that regulates the release of proinflammatory cytokines such as interleukin-1β in response to exogenous pathogens and endogenous danger signals. Evidence from studies involving human genetics, human ex vivo mononuclear cell responses, and in vivo and in vitro murine models confirms the importance of the inflammasome and interleukin-1β in the pathogenesis of several inherited and complex diseases. The availability of several effective interleukin-1β targeted therapies has allowed for successful proof-of-concept studies in several of these disorders. However, many other diseases are likely to be mediated by the inflammasome and interleukin-1β, providing additional targets in the future.
- Inflammasome and IL-1β-Mediated Disorders
- Open Access
- Available under Open Access This content is freely available online to anyone, anywhere at any time.
Current Allergy and Asthma Reports
Volume 10, Issue 4 , pp 229-235
- Cover Date
- Print ISSN
- Online ISSN
- Current Science Inc.
- Additional Links
- Biologic therapy
- Industry Sectors
- Author Affiliations
- 1. Division of Allergy and Immunology, University of California at San Diego and Rady Children’s Hospital of San Diego, 9500 Gilman Drive, La Jolla, CA, 92093, USA
- 2. University of Colorado Health Sciences Center and Allergy and Asthma Consultants of Montana, 2055 North 22nd, Suite 1, Bozeman, MT, 59718, USA